What is HC Wainwright’s Estimate for GALT Q1 Earnings?

Galectin Therapeutics Inc. (NASDAQ:GALT) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Galectin Therapeutics in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst M. Keller anticipates that the company will post earnings of ($0.06) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.09) EPS and Q4 2026 earnings at ($0.10) EPS.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Galectin Therapeutics in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $11.00.

Galectin Therapeutics Price Performance

NASDAQ:GALT opened at $2.67 on Thursday. The company has a market cap of $175.77 million, a P/E ratio of -5.56 and a beta of 1.03. The firm’s fifty day moving average price is $2.95 and its two-hundred day moving average price is $4.19. Galectin Therapeutics has a one year low of $1.12 and a one year high of $7.13.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.02.

Institutional Trading of Galectin Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of GALT. Bank of America Corp DE boosted its holdings in Galectin Therapeutics by 101.4% in the 4th quarter. Bank of America Corp DE now owns 38,358 shares of the company’s stock valued at $49,000 after purchasing an additional 19,316 shares during the period. XTX Topco Ltd increased its holdings in shares of Galectin Therapeutics by 226.6% during the second quarter. XTX Topco Ltd now owns 42,805 shares of the company’s stock worth $90,000 after purchasing an additional 29,699 shares during the period. Marshall Wace LLP acquired a new stake in shares of Galectin Therapeutics in the second quarter valued at approximately $64,000. Vivaldi Capital Management LP raised its position in shares of Galectin Therapeutics by 210.0% in the second quarter. Vivaldi Capital Management LP now owns 172,443 shares of the company’s stock valued at $364,000 after buying an additional 116,815 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Galectin Therapeutics in the second quarter valued at approximately $1,580,000. Institutional investors and hedge funds own 11.68% of the company’s stock.

Insider Activity at Galectin Therapeutics

In other Galectin Therapeutics news, insider Khurram Jamil sold 21,446 shares of the company’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $3.65, for a total value of $78,277.90. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Joel Lewis sold 37,698 shares of the stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $3.58, for a total value of $134,958.84. Following the transaction, the chief executive officer owned 832,592 shares in the company, valued at $2,980,679.36. The trade was a 4.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 158,460 shares of company stock worth $596,165 in the last ninety days. 52.60% of the stock is owned by company insiders.

About Galectin Therapeutics

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.